CDK4 and neoplasm: Indeed, a preclinical study by Laroche-Clary et al. found that compared to monotherapy, a combination of the MDM2 inhibitor RG7388 (PubChem CID: 53358942) with the CDK4/6 inhibitor palbociclib led to significantly reduced tumor growth in DDLPS xenografts and increased progression-free survival.158